Search

Your search keyword '"eculizumab"' showing total 7,743 results

Search Constraints

Start Over You searched for: Descriptor "eculizumab" Remove constraint Descriptor: "eculizumab"
7,743 results on '"eculizumab"'

Search Results

1. United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use.

7. Eculizumab for Shiga-toxin-induced hemolytic uremic syndrome in adults with neurological involvement.

19. Eculizumab Versus Rituximab for Refractory Antiacetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: A Single‐Center Experience.

20. Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH): Pooled Results From the Phase 3 COMMODORE Studies.

21. Successful eculizumab treatment as an adjunctive therapy to desensitization in ABO-incompatible living donor kidney transplantation and its molecular phenotypes.

22. Relapsing meningitis and limbic encephalitis in anti-AQP4-Ab-associated neuromyelitis optica spectrum disorder.

23. Acute Myeloid Leukemia as a Trigger for Hemolytic–Uremic Syndrome.

24. Beyond Recycling Antibodies: Crovalimab's Molecular Design Enables Four-Weekly Subcutaneous Injections for PNH Treatment.

25. Complement system activation: bridging physiology, pathophysiology, and therapy.

26. Bilateral Retinal Venous Occlusion in Atypical Hemolytic-Uremic Syndrome Due to Complement Factor H Mutation.

27. Spontaneous Extradural Hematoma in a Sickle Cell Anemia Patient with Hyperinflammation and Thrombotic Microangiopathy Successfully Treated with Eculizumab: A Case Report and Review of the Literature.

28. Anti-CFH-associated hemolytic uremic syndrome: do we still need plasma exchange?

29. Inhibítory komplementu ekulizumab a ravulizumab v liečbe generalizovanej myasténie gravis (gMG).

30. Complement or insult: the emerging link between complement cascade deficiencies and pathology of myeloid malignancies.

31. The complement model disease paroxysmal nocturnal hemoglobinuria.

32. Using genetics to explore complement C5 as a druggable protein in periodontitis.

33. Carfilzomib-induced thrombotic microangiopathy (TMA) refractory to eculizumab: A case report and literature review.

34. Thrombotische Mikroangiopathie als seltene Komplikation nach Lungentransplantation.

35. Systemic lupus erythematosus presenting with atypical hemolytic uremic syndrome: a case report and review of the literature.

36. Meningococcal Carriage in Children with Atypical Hemolytic Uremic Syndrome Receiving Eculizumab Therapy.

37. Lupusnephritis und assoziierte thrombotische Mikroangiopathie.

38. Case report: Timing of eculizumab treatment in catastrophic antiphospholipid syndrome.

39. Closing remarks from the IIGANN2023 Tokyo symposium—40 years of study progress in IgA nephropathy.

40. Distinctive antibody responses to Mycobacterium tuberculosis in pulmonary and brain infection.

41. A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients.

42. Efficacy and safety of eculizumab in Guillain‐Barré syndrome: A phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial.

43. Population pharmacokinetic, pharmacodynamic and efficacy modeling of SB12 (proposed eculizumab biosimilar) and reference eculizumab.

44. Thrombotic microangiopathy (TMA) associated with pregnancy: role of the clinical laboratory in differential diagnosis.

45. Microangiopatía trombótica (MAT) asociada al embarazo: papel del laboratorio clínico en el diagnóstico diferencial.

46. Monocyte NLRP3 inflammasome and interleukin-1β activation modulated by alpha-1 antitrypsin therapy in deficient individuals.

47. Targeted management of coexistent severe thrombophilias—A case report of a successful pregnancy despite paroxysmal nocturnal hemoglobinuria and hereditary protein C deficiency

48. Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU) (EspacECU)

Catalog

Books, media, physical & digital resources